Journal of Thoracic Oncology Oncology
Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy
The publisher did not provide an abstract — full text is available via the link below.